The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity (Q38170310)

30 August 2017

The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity (English)

1 reference

30 August 2017

5

1 reference

30 August 2017

C Cuerda

1

1 reference

30 August 2017

C Velasco

series ordinal

2

1 reference

30 August 2017

J Merchán-Naranjo

series ordinal

3

1 reference

30 August 2017

P García-Peris

series ordinal

4

1 reference

30 August 2017

11 December 2013

1 reference

European Journal of Clinical Nutrition

30 August 2017

1 reference

30 August 2017

68

1 reference

30 August 2017

146-152

1 reference

30 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/ejcn.2013.253

30 August 2017

0 references

cites work

Antipsychotic Use and Expenditure in the United States

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

CATIE and CUtLASS: can we handle the truth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Antipsychotic drugs and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Increased food intake and energy expenditure following administration of olanzapine to healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

The potential role of appetite in predicting weight changes during treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Effects of olanzapine and haloperidol on the metabolic status of healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Clozapine's effects on body weight and resting metabolic rate: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Low-fat oxidation may be a factor in obesity among men with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Energy expenditure and physical activity in clozapine use: implications for weight management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Dietary intake profile of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Clinical use of the respiratory quotient obtained from indirect calorimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

12 December 2020

Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.

1 reference

12 December 2020

Lessons to take home from CATIE.

1 reference

12 December 2020

The unhealthy lifestyle of people with schizophrenia

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Energy expenditure: components and evaluation methods

1 reference

12 December 2020

Antipsychotic use and expenditure in the United States.

1 reference

12 December 2020

Adiposity and eating behaviors in patients under second generation antipsychotics

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004

1 reference

12 December 2020

Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine

1 reference

12 December 2020

Energy expenditure and fat-free mass in men and women

1 reference

12 December 2020

Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization

1 reference

12 December 2020

Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls

1 reference

12 December 2020

The American Cancer Society, American Diabetes Association, and American Heart Association joint statement on preventing cancer, cardiovascular disease, and diabetes: where are the social determinants?

1 reference

https://api.crossref.org/works/10.1038%2FEJCN.2013.253

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/EJCN.2013.253

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference